Autoimmune Responses in Oncology: Causes and Significance
Specific anti-tumor immune responses have proven to be pivotal in shaping tumorigenesis and tumor progression in solid cancers. These responses can also be of an autoimmune nature, and autoantibodies can sometimes be present even before the onset of clinically overt disease. Autoantibodies can be ge...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/15/8030 |
| _version_ | 1797525515565793280 |
|---|---|
| author | Halin Bareke Pablo Juanes-Velasco Alicia Landeira-Viñuela Angela-Patricia Hernandez Juan Jesús Cruz Lorena Bellido Emilio Fonseca Alfonssina Niebla-Cárdenas Enrique Montalvillo Rafael Góngora Manuel Fuentes |
| author_facet | Halin Bareke Pablo Juanes-Velasco Alicia Landeira-Viñuela Angela-Patricia Hernandez Juan Jesús Cruz Lorena Bellido Emilio Fonseca Alfonssina Niebla-Cárdenas Enrique Montalvillo Rafael Góngora Manuel Fuentes |
| author_sort | Halin Bareke |
| collection | DOAJ |
| description | Specific anti-tumor immune responses have proven to be pivotal in shaping tumorigenesis and tumor progression in solid cancers. These responses can also be of an autoimmune nature, and autoantibodies can sometimes be present even before the onset of clinically overt disease. Autoantibodies can be generated due to mutated gene products, aberrant expression and post-transcriptional modification of proteins, a pro-immunogenic milieu, anti-cancer treatments, cross-reactivity of tumor-specific lymphocytes, epitope spreading, and microbiota-related and genetic factors. Understanding these responses has implications for both basic and clinical immunology. Autoantibodies in solid cancers can be used for early detection of cancer as well as for biomarkers of prognosis and treatment response. High-throughput techniques such as protein microarrays make parallel detection of multiple autoantibodies for increased specificity and sensitivity feasible, affordable, and quick. Cancer immunotherapy has revolutionized cancer treatments and has made a considerable impact on reducing cancer-associated morbidity and mortality. However, immunotherapeutic interventions such as immune checkpoint inhibition can induce immune-related toxicities, which can even be life-threatening. Uncovering the reasons for treatment-induced autoimmunity can lead to fine-tuning of cancer immunotherapy approaches to evade toxic events while inducing an effective anti-tumor immune response. |
| first_indexed | 2024-03-10T09:14:57Z |
| format | Article |
| id | doaj.art-684f6e0366f84f76b96d1caf4df74a78 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:14:57Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-684f6e0366f84f76b96d1caf4df74a782023-11-22T05:42:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012215803010.3390/ijms22158030Autoimmune Responses in Oncology: Causes and SignificanceHalin Bareke0Pablo Juanes-Velasco1Alicia Landeira-Viñuela2Angela-Patricia Hernandez3Juan Jesús Cruz4Lorena Bellido5Emilio Fonseca6Alfonssina Niebla-Cárdenas7Enrique Montalvillo8Rafael Góngora9Manuel Fuentes10Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Institute of Health Sciences, Marmara University, Istanbul 34722, TurkeyDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainMedical Oncology Service, Hospital Universitario de Salamanca-IBSAL, 37007 Salamanca, SpainMedical Oncology Service, Hospital Universitario de Salamanca-IBSAL, 37007 Salamanca, SpainMedical Oncology Service, Hospital Universitario de Salamanca-IBSAL, 37007 Salamanca, SpainDepartment of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, University of Salamanca, 37007 Salamanca, SpainDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainDepartment of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, SpainSpecific anti-tumor immune responses have proven to be pivotal in shaping tumorigenesis and tumor progression in solid cancers. These responses can also be of an autoimmune nature, and autoantibodies can sometimes be present even before the onset of clinically overt disease. Autoantibodies can be generated due to mutated gene products, aberrant expression and post-transcriptional modification of proteins, a pro-immunogenic milieu, anti-cancer treatments, cross-reactivity of tumor-specific lymphocytes, epitope spreading, and microbiota-related and genetic factors. Understanding these responses has implications for both basic and clinical immunology. Autoantibodies in solid cancers can be used for early detection of cancer as well as for biomarkers of prognosis and treatment response. High-throughput techniques such as protein microarrays make parallel detection of multiple autoantibodies for increased specificity and sensitivity feasible, affordable, and quick. Cancer immunotherapy has revolutionized cancer treatments and has made a considerable impact on reducing cancer-associated morbidity and mortality. However, immunotherapeutic interventions such as immune checkpoint inhibition can induce immune-related toxicities, which can even be life-threatening. Uncovering the reasons for treatment-induced autoimmunity can lead to fine-tuning of cancer immunotherapy approaches to evade toxic events while inducing an effective anti-tumor immune response.https://www.mdpi.com/1422-0067/22/15/8030autoantibodiessolid cancerscancer immunotherapybiomarkerautoimmunityimmune-related adverse effects |
| spellingShingle | Halin Bareke Pablo Juanes-Velasco Alicia Landeira-Viñuela Angela-Patricia Hernandez Juan Jesús Cruz Lorena Bellido Emilio Fonseca Alfonssina Niebla-Cárdenas Enrique Montalvillo Rafael Góngora Manuel Fuentes Autoimmune Responses in Oncology: Causes and Significance International Journal of Molecular Sciences autoantibodies solid cancers cancer immunotherapy biomarker autoimmunity immune-related adverse effects |
| title | Autoimmune Responses in Oncology: Causes and Significance |
| title_full | Autoimmune Responses in Oncology: Causes and Significance |
| title_fullStr | Autoimmune Responses in Oncology: Causes and Significance |
| title_full_unstemmed | Autoimmune Responses in Oncology: Causes and Significance |
| title_short | Autoimmune Responses in Oncology: Causes and Significance |
| title_sort | autoimmune responses in oncology causes and significance |
| topic | autoantibodies solid cancers cancer immunotherapy biomarker autoimmunity immune-related adverse effects |
| url | https://www.mdpi.com/1422-0067/22/15/8030 |
| work_keys_str_mv | AT halinbareke autoimmuneresponsesinoncologycausesandsignificance AT pablojuanesvelasco autoimmuneresponsesinoncologycausesandsignificance AT alicialandeiravinuela autoimmuneresponsesinoncologycausesandsignificance AT angelapatriciahernandez autoimmuneresponsesinoncologycausesandsignificance AT juanjesuscruz autoimmuneresponsesinoncologycausesandsignificance AT lorenabellido autoimmuneresponsesinoncologycausesandsignificance AT emiliofonseca autoimmuneresponsesinoncologycausesandsignificance AT alfonssinanieblacardenas autoimmuneresponsesinoncologycausesandsignificance AT enriquemontalvillo autoimmuneresponsesinoncologycausesandsignificance AT rafaelgongora autoimmuneresponsesinoncologycausesandsignificance AT manuelfuentes autoimmuneresponsesinoncologycausesandsignificance |